Clear Street Group Inc. Makes New $5.07 Million Investment in Tharimmune, Inc. $THAR

Clear Street Group Inc. acquired a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,671,836 shares of the company’s stock, valued at approximately $5,066,000. Clear Street Group Inc. owned approximately 4.43% of Tharimmune at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Drucker Wealth 3.0 LLC acquired a new position in Tharimmune during the third quarter worth $29,000. Essex LLC acquired a new position in Tharimmune during the fourth quarter worth $31,000. XTX Topco Ltd acquired a new position in Tharimmune during the second quarter worth $25,000. State Street Corp raised its stake in Tharimmune by 109.0% during the fourth quarter. State Street Corp now owns 36,621 shares of the company’s stock worth $111,000 after acquiring an additional 19,100 shares in the last quarter. Finally, Franklin Resources Inc. bought a new stake in shares of Tharimmune during the second quarter worth $88,000. 1.16% of the stock is currently owned by institutional investors and hedge funds.

Tharimmune Stock Performance

Shares of THAR stock opened at $3.09 on Friday. The stock’s fifty day moving average is $3.18 and its 200-day moving average is $3.41. The stock has a market capitalization of $116.59 million, a PE ratio of -0.77 and a beta of 1.43. Tharimmune, Inc. has a 52 week low of $0.95 and a 52 week high of $9.08.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.